Description: Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Home Page: www.fortebiorx.com
3060 Pegasus Park Drive
Dallas,
TX
75247
United States
Phone:
310 618 6994
Officers
| Name | Title |
|---|---|
| Dr. Paul A. Wagner Ph.D. | CEO & Chairman |
| Mr. Antony A. Riley CPA | Chief Financial Officer |
| Dr. Hubert C. Chen M.D. | Pres & Chief Scientific Officer |
| Mr. Christopher Roenfeldt | Chief Operating Officer |
| Mr. Steven Ruhl | Chief Technical Officer |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4739 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |